32nd Annual North American Cystic Fibrosis Conference

Oct 18, 2018 ‐ Oct 20, 2018



Sessions

P1--*Improving Outcomes of Infections in the Age of CFTR Modulators

Oct 18, 2018 4:30pm ‐ Oct 18, 2018 6:00pm

In this session, Dr. Lisa Saiman will address the challenges of infections in people with CF and discuss why infections remain a major focus of the CF community, even in the era of effective CFTR modulators. She will provide an overview of CF infections, describe ongoing studies to increase our understanding of CF microorganisms and their optimal treatment, and discuss current strategies to develop new anti-infective agents to treat even the most difficult infections.

Learning Objectives:

  • Identify ongoing challenges in the treatment of infections in people with CF, including the potential impact of CFTR modulators on infections.
  • Describe ongoing studies to improve our understanding of CF microorganisms including detection, diagnosis and optimal treatment.
  • Discuss strategies to develop new anti-infective therapies to treat people with CF.

Plenary Leader(s):

P2--*Anti-inflammatories & Mucociliary Clearance Therapies in the Age of CFTR Modulators

Oct 19, 2018 9:00am ‐ Oct 19, 2018 10:00am

This plenary will review the effect of CFTR dysfunction and CFTR restoration on both inflammation and mucociliary clearance in individuals with CF. Current and future therapeutic strategies to address inflammation and mucociliary clearance will be discussed, as well as how these strategies have potential to benefit both those patients using CFTR modulators and those not eligible for modulators.

Learning Objectives:

  • Identify current strategies to develop new therapies that treat inflammation in cystic fibrosis.
  • Identify current strategies to develop new therapies that improve mucociliary clearance in cystic fibrosis.
  • Describe the impact of CFTR modulators on inflammation and mucociliary clearance and why continued development of therapies is needed.

Plenary Leader(s):
  • Felix Ratjen, M.D., Ph.D., Division Head/Professor University

P3--*Partnering: The Oldest New Idea to Improve CF Care

Oct 20, 2018 9:00am ‐ Oct 20, 2018 10:00am

Central to the management of cystic fibrosis are the relationships that people with CF and their families build with their clinical care teams. As people with CF live longer, their disease increases in complexity, making coordination and individualized care ever more dependent upon these foundational relationships. Actively partnering in health care is a learning process and although, highly regarded, realizing and maintaining full partnership can be challenging. This plenary will walk through the evolution of partnering, specifically in CF care and more broadly in the context of health care and society, further thinking by exploring the tensions impacting partnership, and highlight new strategies supported by the CF Foundation, so that all people living with CF can better balance their daily care while attaining personal goals. The plenary will end with a panel discussion between an adult living with CF, a parent, and a healthcare professional from the CF Foundation.

Learning Objectives:

  • Describe the evolution of partnerships in the context of society, health care and CF care.
  • Explore the tensions underlying the shift away from a traditional, clinician-driven approach toward a more collaborative partnership with patients.
  • Apply innovative ways to approach partnering in CF care.

Plenary Leader(s):
  • Maren Batalden, M.D., Associate Chief Quality Officer/Assistant Professor
Plenary Panelist(s):

S01--APP&D-INF/MIC-NT: External Triggers of CF Airway Disease: Instigators & Perpetrators

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

As CF lungs at birth shows few signs of infection and inflammation, an emerging concept is that external challenges may precipitate the onset of infection and inflammation that persist into chronic lung disease. External challenges such as microaspiration of commensal upper airway bacteria or respiratory virus infections are potential external challenges that young CF lungs may not resolve as effectively as young non-CF lungs. This Symposium reviews the current knowledge of the status of the young CF lung and what the early challenges to the maintenance of airway health may be. By identifying external triggers of CF airway disease, strategies can be developed to minimize the risk of compromising the young CF.

Learning Objectives: 

  • Summarize the evolution of lung disease in the CF lung with age.
  • Appraise the changing microbiota as it evolves in the CF lung over time.
  • Evaluate the relative contribution of microaspiration versus respiratory virus infection. 

Note: Speaker Stephen Stick's presentation was not recorded at his request.

Symposium Chair(s): Symposium Speaker(s):

S02--CLIN: CFRD Across the Lifespan

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

This symposium will highlight several key aspects of cystic fibrosis related diabetes pathophysiology and management that are specific to different time periods during the life of individuals with CF. Specifically, speakers will address topics including glycemic abnormalities occurring in childhood that progress to CFRD, challenges in management of CFRD including hypoglycemia and barriers to obtaining expert medical care, and CFRD treatment regimens including novel future therapies.

Learning Objectives:

  • Discuss the early abnormalities in glycemic regulation that precede CF related diabetes.
  • Assess challenges in the management of CFRD including hypoglycemia and barriers to obtaining appropriate medical care.
  • Identify current treatment regimens for CFRD as well as novel developing therapies that may become available in the future.

Symposium Chair(s): Symposium Speaker(s):

S03--CLIN-NRS-PT&RT: Year(s) in Review

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

This is a new symposium at NACFC. The goal of this session is to review important publications over the last 2 years. The audience for this session is the entire cystic fibrosis team and the focus of the presentations will be on providing information in a way to help a patient that a member of the audience may see in clinic or the hospital after NACFC. The four topics will be presented by international experts in the field. Recent publications will be discussed for each topic: 1) Challenges in the diagnosis of CF infants following newborn screening; 2) Pulmonary exacerbation's and what we have learned from the STOP studies; 3) Mental health in CF and 4) an update on CFTR modulators. Attendees will be provided with a publication list for each of the topics.

Learning Objectives:

  • Summarize an approach to the challenge in cystic fibrosis infants with inconclusive diagnosis following newborn screening.
  • Describe the up to date approach to pulmonary exacerbations and for CFTR modulators.
  • Assess the current literature regarding mental heath in cystic fibrosis.

Symposium Chair(s): Symposium Speaker(s):

S04--GMS-NT: Model Systems Meet Therapeutics

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

The number of available model systems for laboratory study of CF continues to expand at a rapid pace. Current options range from genetically modified cell lines or animals to primary human cell models, each offering unique benefits. Many of these models have contributed to the development of current and emerging therapies for patients with CF. Moreover, the use of novel models at the interface of research and clinical care is expanding access to these medications. This symposium will focus on the use of CF-relevant model systems across the therapeutic pipeline from drug screening and development to personalized clinical approaches. Particular emphasis will be placed on the benefits and limitations of each discussed model, and how the choice of each model matches and empowers the study of the therapy in question.

Learning Objectives:

  • Demonstrate the wide range of complimentary CF-relevant model systems currently in use to study therapeutics.
  • Discuss the benefits and limitations of CF-relevant cell line, animal, and primary cell-based model systems relative to specific treatments or drugs.
  • Describe the utility of each unique model system at different stages of the drug development pipeline from discovery to the clinic.

Note: Speaker Christine Bear's presentation was not recorded at her request. 

Symposium Chair(s): Symposium Speaker(s):

S05--INF/MIC: Antimicrobial Resistance

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

This session will review the objectives and preliminary findings of the International Working Group on Antimicrobial Resistance in CF.

Learning Objectives:

  • Define antimicrobial resistance in CF.
  • Describe the clinical relevance of antimicrobial resistance in CF.
  • Discuss the role of antimicrobial stewardship in CF.

Note: Speaker Ranjani Somayaji's presentation was not recorded at her request. 

Symposium Chair(s): Symposium Speaker(s):

S06--NRS-CLIN: *Controversial Practices - Helpful or Harmful

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

Overview of controversial therapies, including herbal products, nutritional supplements, salt rooms, Indrepta, vaping and other inhalants and medical/legalized marijuana.

Learning Objectives:

  • Define prevalence of CF patients' use of complimentary and alternative medicine and therapies and current practices with patients discussing their use of these products with care centers.
  • Summarize knowledge, risk perception, behaviors, education and perceived patient benefits about vaping, e-cigarettes, and other inhaled agents.
  • Review potential best practices regarding medical marijuana and transplant eligibility and palliative care uses.

Symposium Chair(s): Symposium Speaker(s):

S07--SW/PSYCH-NTR-PT&RT: *Caroline McPherson Symposium: Healthy Habits: Promoting Physical & Mental Health Through Sleep, Exercise, & Nutrition

Oct 18, 2018 2:00pm ‐ Oct 18, 2018 3:25pm

Rapidly advancing treatments of cystic fibrosis have increased the expected life span and quality of life trajectories for persons with CF. This symposium will: 1) Explore the potential for further enhancements of mental and physical health throughout the life-cycle through evidence-based recommendations for sleep, exercise, and nutrition. 2) Enable persons with CF and healthcare professionals to co-produce individual plans for healthy habits. Additionally, an adult CF patient will present his perspective on the impact that sleep, exercise, and nutrition has had on his life and well-being.

Learning Objectives:

  • Summarize current knowledge regarding the impact of sleep on health in cystic fibrosis and identify strategies for improving sleep using cognitive behavioral techniques.
  • Describe the benefits of engaging in a pulmonary rehabilitation program and utilizing individualized exercise and fitness regimens to optimize pulmonary and mental health outcomes.
  • Examine evolving nutrition research that goes beyond the FEV1/BMI association and high fat/high calorie diets. Discuss how dietary composition and personalized medical nutrition therapy can impact CF outcomes.

Symposium Chair(s): Symposium Speaker(s):
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content